IMCR
Immunocore Holdings Plc
NASDAQ · Healthcare · Biotechnology · GB
$32.00
−0.93%Sep 14, 2026, 11:00 UTC
Immunocore Holdings plc announced that target enrollment of 540 patients has been achieved in the registrational Phase 3 TEBE-AM trial evaluating KIMMTRAK (tebentafusp) as monotherapy and with pembrolizumab in previously treated advanced melanoma.
Source:Aug 6, 2026, 00:00 UTC
Immunocore Holdings plc reported Q2 2026 net revenue of $115.9 million, up 18% year-over-year, with a net loss of $0.8 million and diluted EPS of -$0.02.